Tolvaptan

ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan

PRINCETON, N.J., Sept. 19, 2007 -- A single dose of Otsukas investigational oral medication tolvaptan, a vasopressin receptor antagonist, resulted in favorable changes in hemodynamics associated with a significant increase in urine output in patients with advanced heart failure (ADHF) who particip...

New Class of Drugs Might Treat Many Conditions

...legs, and tocolysis, (premature labor, leading to premature birth). Another subclass of vaptans that include mozavaptan, lixivaptan, satavaptan and tolvaptan are diuretics, which remove water from the body, while maintaining the body's electrolyte, or salt mineral, balance. Other diuretics don't maintain th...

Heart Failure Medication Provides Some Symptom Relief

...in Antagonism in Heart Failure: Outcome Study With tolvaptan (EVEREST) trial, examined the long-term clinical o...-up of 9.9 months, 25.9 percent of patients in the tolvaptan group and 26.3 percent in the placebo group died. ...on for heart failure occurred in 42 percent of the tolvaptan patients and 40.2 percent of the placebo group pat...

New Drug That Might Help Congestive Heart Failure Patients

...sening kidney function. Researchers say a new drug tolvaptan may be more effective than existing medications fo...ls and causes fluid retention. Researchers studied tolvaptan -- a drug that targets vasopressin -- to determine...r 30 milligrams, 60 milligrams or 90 milligrams of tolvaptan or a placebo in addition to standard medications. ...

Tolvaptan in Medical Technology

ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials

...to clarify the hemodynamic effects of orally dosed tolvaptan in patients with advanced heart failure due to sys...IV) were randomized to double-blind treatment with tolvaptan at a single oral dose of 15, 30, 60 mg or placebo. All three doses of tolvaptan examined in ECLIPSE significantly changed the prim...

Everest Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials

...sin Antagonism in Heart Failure Outcome Study with tolvaptan (EVEREST) published in the March 28 issue of the J... embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient c...ody weight at day seven or discharge.(1) Long-term tolvaptan use did not differ from placebo on either of the s...

Tolvaptan in Biological Technology

U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia

...t, and fluid regulation in and around cells.(ii) Approximately 3.2 million to 6.1 million people in the U.S. suffer from hyponatremia annually.(iii) tolvaptan is an investigational selective antagonist of the vasopressin V2 receptor, which is located predominantly in the kidney and plays a role in the regula...

New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration

...nterests in the U.S. OAI is wholly owned by OPC. tolvaptan is a novel, investigational small molecule designe...cs to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of...eater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with ...